Impact of perivascular adipose tissue attenuation on clinical outcomes after transcatheter aortic valve replacement

Impact of perivascular adipose tissue attenuation on clinical outcomes after transcatheter aortic valve replacement - Impact of perivascular adipose tissue attenuation on clinical outcomes after transcatheter aortic valve replacement

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057107

Enrollment

600

Registered

2025-04-01

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing Transcatheter aortic valve replacement (TAVR) for aortic valve stenosis Patients who have undergone CTA within 6 months prior to TAVR

Exclusion criteria

Exclusion criteria: Patients with inadequate evaluation of CTA Patients who have undergone surgical aortic valve treatment Patients with a follow-up period of within one month

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiovascular Events(MACE): composite endpoint of death from any cause, stroke, or heart failure rehospitalization.	—

Countries

Japan

Contacts

Public ContactHiromasa Otake

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine

hotake@med.kobe-u.ac.jp078-382-5111

Outcome results